DNA damage response as a therapeutic target in gynecological cancers

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Poly ADP-ribose polymerase (PARP) inhibitors are established targeted therapies for BRCA-mutated homologous recombination deficient (HRD) ovarian cancer.
• The success of PARP inhibitors has prompted research into their expanded clinical utility and novel targets within the DNA damage response (DDR) pathway.

Purpose of the Study:

• To review the expanding clinical utility of PARP inhibitors beyond BRCA-mutated ovarian cancer.
• To explore novel targets within the DNA damage response (DDR) pathway for gynecological malignancies.
• To discuss emerging therapeutic strategies including novel DDR inhibitors and combinatorial treatments.

Main Methods:

• Review of early clinical trials assessing PARP inhibition in ovarian cancer.
• Analysis of recent genomic studies identifying homologous recombination gene aberrations.
• Evaluation of ongoing trials for novel DDR inhibitors (e.g., ATR, ATM, WEE1, DNA-PK) and combinatorial therapies.

Main Results:

• PARP inhibitors demonstrate activity in BRCA-wildtype ovarian cancer.
• Germline or somatic aberrations in other homologous recombination genes are prevalent in ovarian cancers.
• PARP inhibition may benefit specific subsets of endometrial and cervical cancers.
• Novel DDR inhibitors and combinatorial strategies show potential for increased therapeutic efficacy.

Conclusions:

• Future selection of gynecological cancer patients for PARP inhibition may be based on comprehensive genomic evaluation of homologous recombination alterations or HRD assays.
• Novel DDR inhibitors are poised to broaden the therapeutic landscape for patients with gynecological malignancies.